Larimar Therapeutics Valuation
| LRMR Stock | USD 3.15 0.06 1.87% |
At this time, the firm appears to be undervalued. Larimar Therapeutics secures a last-minute Real Value of $5.92 per share. The latest price of the firm is $3.15. Our model forecasts the value of Larimar Therapeutics from analyzing the firm fundamentals such as Return On Equity of -0.78, current valuation of 93.97 M, and Shares Owned By Insiders of 1.10 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Larimar Therapeutics' valuation include:
Undervalued
Today
Please note that Larimar Therapeutics' price fluctuation is moderately volatile at this time. Calculation of the real value of Larimar Therapeutics is based on 3 months time horizon. Increasing Larimar Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Larimar stock is determined by what a typical buyer is willing to pay for full or partial control of Larimar Therapeutics. Since Larimar Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Larimar Stock. However, Larimar Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.15 | Real 5.92 | Target 14.67 | Hype 3.14 |
The intrinsic value of Larimar Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Larimar Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Larimar Therapeutics helps investors to forecast how Larimar stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Larimar Therapeutics more accurately as focusing exclusively on Larimar Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Larimar Therapeutics' intrinsic value based on its ongoing forecasts of Larimar Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Larimar Therapeutics' closest peers.
Larimar Therapeutics Cash |
|
Larimar Therapeutics Total Value Analysis
Larimar Therapeutics is now expected to have valuation of 93.97 M with market capitalization of 274.75 M, debt of 5.12 M, and cash on hands of 54.92 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Larimar Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
93.97 M | 274.75 M | 5.12 M | 54.92 M |
Larimar Therapeutics Asset Utilization
One of the ways to look at asset utilization of Larimar is to check how much profit was generated for every dollar of assets it reports. Larimar Therapeutics secures a negative usage of assets of -0.43 %, losing $0.004299 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Larimar Therapeutics shows how discouraging it operates for each dollar spent on its assets.Larimar Therapeutics Profitability Analysis
Based on Larimar Therapeutics' profitability indicators, Larimar Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Larimar Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2014-06-30 | Previous Quarter -26.2 M | Current Value -47.7 M | Quarterly Volatility 7.9 M |
For Larimar Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Larimar Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Larimar Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Larimar Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Larimar Therapeutics over time as well as its relative position and ranking within its peers.
Larimar Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of Larimar Therapeutics is estimated to be -0.4547 with future projections ranging from a low of -0.635 to a high of -0.3475. Larimar Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -1.96. Please be aware that the consensus of earnings estimates for Larimar Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Larimar Therapeutics Earnings Estimation Breakdown
The calculation of Larimar Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Larimar Therapeutics is estimated to be -0.4547 with the future projection ranging from a low of -0.635 to a high of -0.3475. Please be aware that this consensus of annual earnings estimates for Larimar Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.64 Lowest | Expected EPS | -0.35 Highest |
Larimar Therapeutics Earnings Projection Consensus
Suppose the current estimates of Larimar Therapeutics' value are higher than the current market price of the Larimar Therapeutics stock. In this case, investors may conclude that Larimar Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Larimar Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 10 | 62.63% | 0.0 | -0.4547 | -1.96 |
Larimar Therapeutics Ownership Allocation
The majority of Larimar Therapeutics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Larimar Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Larimar Therapeutics. Please pay attention to any change in the institutional holdings of Larimar Therapeutics as this could imply that something significant has changed or is about to change at the company.Larimar Therapeutics Profitability Analysis
Net Loss for the year was (80.6 M) with profit before overhead, payroll, taxes, and interest of 0.About Larimar Therapeutics Valuation
The stock valuation mechanism determines Larimar Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Larimar Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Larimar Therapeutics. We calculate exposure to Larimar Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Larimar Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -286.2 K | -271.9 K |
Larimar Therapeutics Current Valuation Indicators
Larimar Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Larimar Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Larimar Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Larimar Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Larimar Therapeutics' worth.Additional Tools for Larimar Stock Analysis
When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.